Gentle brain zaps may help stroke survivors regain spatial awareness

NCT ID NCT04458974

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This study investigates whether a noninvasive brain stimulation technique called transcranial direct current stimulation (tDCS) can enhance recovery from spatial neglect — a condition where stroke survivors ignore one side of their world. Participants who had a stroke 3 to 12 months ago will receive either real or sham tDCS alongside standard rehabilitation for two weeks. The goal is to see if the brain stimulation reduces neglect symptoms and improves daily functioning.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
transcranial direct current stimulation (tDCS) using a multisite device
What this could lead to
If successful, this approach could offer a safe, noninvasive way to boost recovery from spatial neglect after stroke, improving independence and quality of life.
What could go wrong
This is a small, early-stage trial with only 30 participants, so results may not apply broadly. The treatment effect may be modest or no better than sham stimulation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

20 people

The number who actually took part.

Started

Nov 2019

Finished

Apr 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 89 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Hemorrhagic or ischemic stroke in the right hemisphere. * Stroke 3 to 12 months since the event (regardless of whether or not they have received prior rehabilitation). * 18 to 99 years-old. * Neuroimaging study. * Absence of previous strokes. * Functional capacity that allows him/her to remain seated and active for one hour (Barthel Index score greater than 5 in the item of transfers between chair and bed; this item can be scored from 0 to 15, being 0 totally dependent and 15 totally independent). * Right-handed manual dominance * Neglect scores on at least two of the three tests administered for the assessment of visuospatial neglect. * Signature of informed consent by the patient or his/her legal guardian. Exclusion Criteria: * Dermatological problems (psoriasis, dermatitis on the scalp or face). * Presence of implants or metal parts in the head excluding fillings. * Pacemakers, medication pumps, stimulators (vagal, cerebral, transcutaneous), ventriculoperitoneal shunts or aneurysm clips. * Presence of previous strokes. * Neurological disease other than stroke described in the inclusion criteria. * Severe cognitive impairment assessed using the Mini-mental state examination (MMSE), excluding patients with scores under 24 (the score of MMSE are between 0 and 30, being 0 severe cognitive impairment and 30 no cognitive impairment). * Significant language difficulties that not allow proper understanding of activities or severely limit expression. * History of alcohol or drug abuse. * Moderate or severe active depression. * Uncontrolled medical problems (pathologies in acute phase without medical or pharmacological treatment with proven efficacy or pathologies with imminent life risk). * Pregnancy or suspected pregnancy that will be checked by pregnancy test at the beginning of the study in patients of childbearing age and with the recommendation of the use of contraceptive methods until the end of the intervention.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Neglect, hemispatial are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hospital Beata María Ana (Brain Damage Unit)

    Madrid, Madrid, 28007, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.